These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888 [TBL] [Abstract][Full Text] [Related]
5. [Importance of screening for antibodies to cytomegalovirus in organ transplantation]. Milbradt H; Flik J; Stangel W; Heigel R Beitr Infusionsther; 1990; 26():33-6. PubMed ID: 1703866 [TBL] [Abstract][Full Text] [Related]
6. The problem of cytomegalovirus infection in renal allograft recipients. Kurtz JB; Thompson JF; Ting A; Pinto A; Morris PJ Q J Med; 1984; 53(211):341-9. PubMed ID: 6091169 [TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Peterson PK; Balfour HH; Marker SC; Fryd DS; Howard RJ; Simmons RL Medicine (Baltimore); 1980 Jul; 59(4):283-300. PubMed ID: 6248718 [TBL] [Abstract][Full Text] [Related]
8. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients. Varga M; Rajczy K; Telkes G; Hídvégi M; Péter A; Remport A; Korbonits M; Fazakas J; Toronyi E; Sárváry E; Kóbori L; Járay J Nephrol Dial Transplant; 2008 Aug; 23(8):2673-8. PubMed ID: 18332066 [TBL] [Abstract][Full Text] [Related]
9. Anti-CMV hyperimmune globulin prophylaxis does not prevent CMV disease in CMV-negative renal transplant patients. Pakkala S; Salmela K; Lautenschlager I; Ahonen J; Häyry P Transplant Proc; 1992 Feb; 24(1):283-4. PubMed ID: 1311472 [No Abstract] [Full Text] [Related]
10. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L; Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546 [TBL] [Abstract][Full Text] [Related]
11. Vascular rejection of renal allografts is linked to CMV IgG, positive organ donor. Tenschert W; Dittmer R; Harfmann P; Cremaschi L; Meyer-Moldenhauer WH; Arndt R; Klosterhalfen H Transplant Proc; 1991 Oct; 23(5):2641-2. PubMed ID: 1656565 [No Abstract] [Full Text] [Related]
12. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924 [TBL] [Abstract][Full Text] [Related]
13. The UNOS scientific renal transplant registry. United Network for Organ Sharing. Cecka JM; Terasaki PI Clin Transpl; 1995; ():1-18. PubMed ID: 8794251 [TBL] [Abstract][Full Text] [Related]
14. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients. Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302 [TBL] [Abstract][Full Text] [Related]
15. Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes. Ishibashi K; Tokumoto T; Tanabe K; Shirakawa H; Hashimoto K; Kushida N; Yanagida T; Inoue N; Yamaguchi O; Toma H; Suzutani T Clin Infect Dis; 2007 Jul; 45(1):60-7. PubMed ID: 17554702 [TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies. Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495 [TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus infection in seronegative patients treated with prophylaxis: case-controlled study. Moreno de la Higuera Díaz MA; Calvo Romero N; Sánchez-Fructuoso A; Conesa J; Marques Vidas M; Prats D; Barrientos Guzmán A Transplant Proc; 2007 Sep; 39(7):2231-2. PubMed ID: 17889147 [TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Verdonck LF; de Graan-Hentzen YC; Dekker AW; Mudde GC; de Gast GC Bone Marrow Transplant; 1987 Jun; 2(1):73-8. PubMed ID: 2844337 [TBL] [Abstract][Full Text] [Related]
19. The UNOS renal transplant registry. Cecka JM Clin Transpl; 2001; ():1-18. PubMed ID: 12211771 [TBL] [Abstract][Full Text] [Related]
20. Review of the CMV in renal transplantation. Pescovitz MD Saudi J Kidney Dis Transpl; 2007 Nov; 18(4):505-11. PubMed ID: 17951935 [No Abstract] [Full Text] [Related] [Next] [New Search]